EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd‐Generation Bruton Tyrosine Kinase Inhibitor‐Based Therapies

Benjamin J Lee iD, Jenny Liu, Shawn P Griffin iD, Jean Doh iD, Stefan O Ciurea iD, Piyanuch Kongtim iD, Elizabeth A Brem iD

Cancer Medicine · 2024

DOI: 10.1002/cam4.70310 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Benjamin J Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of California Irvine Health, Orange, California, USA. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Agammaglobulinaemia Tyrosine Kinase, Protein Kinase Inhibitors. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Blastoid variant‐mantle cell lymphoma (BV‐MCL) represents an aggressive subset of patients with no established standard of care treatment approach.

Methods

We performed a retrospective analysis of the clinical characteristics and outcomes of 17 de novo BV‐MCL patients treated at our institution between May 2009 and September 2023. In addition, we reviewed the literature supporting 2nd/3rd generation Bruton's Tyrosine‐kinase (BTKi)‐based therapies for upfront management.

Results

The complete response rate to frontline and salvage therapy was 66.7% and 25%, respectively. Two‐year overall survival (OS) was low at 62.5% (95% CI, 34.7%–81.1%). Variables associated with higher OS included receipt of consolidative HSCT ( p = 0.017), TP53‐wild type ( p = 0.031), intermediate‐ versus high‐risk Mantle Cell Lymphoma Prognostic Index score ( p = 0.026), and achieving complete response with induction therapy ( p = 0.027).

Discussion

Treatment outcomes with chemo‐immunotherapy in BV‐MCL patients are poor, especially among TP53‐mutated patients. Recent findings describing positive outcomes with novel BTKi‐based therapies are encouraging and should be considered in this high‐risk population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Mantle-CellAgammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsHumansMaleFemaleAgedMiddle AgedRetrospective StudiesAntineoplastic Combined Chemotherapy ProtocolsAged, 80 and overAdultTreatment OutcomeHematopoietic Stem Cell TransplantationSalvage TherapyTumor Suppressor Protein p53Tyrosine Kinase Inhibitors

Stichwörter der Autor:innen

Bruton tyrosine kinase inhibitorblastoid variantmantle cell lymphoma

Substanzen

Agammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsBTK protein, humanTumor Suppressor Protein p53Tyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy, University of California Irvine Health, Orange, California, USA.
  • Department of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, California, USA.
  • Department of Medicine, Division of Hematology Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Health, Orange, California, USA.

ORCID-Profile: Benjamin J Lee, Shawn P Griffin, Jean Doh, Stefan O Ciurea, Piyanuch Kongtim, Elizabeth A Brem

Förderung

  • NCI NIH HHS

Zitieren

APA

Lee, B. J., Liu, J., Griffin, S. P., Doh, J., Ciurea, S. O., Kongtim, P., & Brem, E. A. (2024). Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd‐Generation Bruton Tyrosine Kinase Inhibitor‐Based Therapies. Cancer Medicine. https://doi.org/10.1002/cam4.70310

Vancouver

Lee BJ, Liu J, Griffin SP, Doh J, Ciurea SO, Kongtim P, et al. Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd‐Generation Bruton Tyrosine Kinase Inhibitor‐Based Therapies. Cancer Medicine. 2024. doi:10.1002/cam4.70310

BibTeX
@article{Lee2024,
  author = {Lee, Benjamin J and Liu, Jenny and Griffin, Shawn P and Doh, Jean and Ciurea, Stefan O and Kongtim, Piyanuch and Brem, Elizabeth A},
  title = {Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd‐Generation Bruton Tyrosine Kinase Inhibitor‐Based Therapies},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70310}
}
Kostenlos starten →